Trial Profile
Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous System
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications CNS cancer; Gliosarcoma; Sarcoma
- Focus Therapeutic Use
- 24 Mar 2022 Status changed from completed to discontinued.
- 03 Apr 2021 Status changed from recruiting to completed.
- 20 Jun 2020 Planned End Date changed from 30 Sep 2022 to 30 Sep 2024.